Mutant lipooligosaccharide-based conjugate vaccine demonstrates a broad-spectrum effectiveness against Moraxella catarrhalis

Vaccine

Volumn 29, Issue 25, 2011, Pages 4210-4217

  Ren, Dabin ^a   Yu, Shengqing ^a,f   Gao, Song ^a,g   Peng, Daxin ^a,g   Petralia, Ronald S ^a   Muszynski, Artur ^b   Carlson, Russell W ^b   Robbins, John B ^c   Tsai, Chao Ming ^d   Lim, David J ^e   Gu, Xin Xing ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e HOUSE EAR INSTITUTE   (United States)

^f INSTITUTE OF PLANT PROTECTION   (China)

^g YANGZHOU UNIVERSITY   (China)

Author keywords

Conjugate vaccine; Conserved antigen; Cross reactivity; Lipooligosaccharide mutant; Moraxella catarrhalis

Indexed keywords

ADJUVANT; ANTISERUM; COMPLEMENT; EPITOPE; GALACTOSE; IMMUNOGLOBULIN G; LIPOOLIGOSACCHARIDE TETANUS TOXOID CONJUGATE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; AUTOIMMUNITY; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CROSS REACTION; DETOXIFICATION; DRUG CONJUGATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MORAXELLA CATARRHALIS; MUTANT; NONHUMAN; PRIORITY JOURNAL; PURIFICATION; RABBIT; SEROTYPE; TRANSMISSION ELECTRON MICROSCOPY; WILD TYPE;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT SYSTEM PROTEINS; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; LIPOPOLYSACCHARIDES; MORAXELLA (BRANHAMELLA) CATARRHALIS; MORAXELLACEAE INFECTIONS; RABBITS; TETANUS TOXOID; VACCINATION; VACCINES, CONJUGATE;

EID: 79956201645     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.102     Document Type: Article

References (44)

1. Perez Vidakovics M.L., Riesbeck K. Virulence mechanisms of Moraxella in the pathogenesis of infection. Curr Opin Infect Dis 2009, 22:279-285.
2. Corbeel L. What is new in otitis media?. Eur J Pediatr 2007, 166:511-519.
3. Murphy T.F., Parameswaran G.I. Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis 2009, 49:124-131.
4. Murphy T.F., Brauer A.L., Grant B.J., Sethi S. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 2005, 172:195-199.
5. American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics 2004;113:1451-65.
6. Verduin C.M., Hol C., Fleer A., van Dijk H., van Belkum A. Moraxella catarrhalis: from emerging to established pathogen. Clin Microbiol Rev 2002, 15:125-144.
7. Wardle J.K. Branhamella catarrhalis as an indirect pathogen. Drugs 1986, 31(Suppl. 3):93-96.
8. Mawas F., Ho M.M., Corbel M.J. Current progress with Moraxella catarrhalis antigens as vaccine candidates. Expert Rev Vaccines 2009, 8:77-90.
9. Murphy T.F. Vaccine development for Moraxella catarrhalis: rationale, approaches and challenges. Expert Rev Vaccines 2009, 8:655-658.
10. Chen D., McMichael J.C., VanDerMeid K.R., Hahn D., Mininni T., Cowell J., et al. Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization. Infect Immun 1996, 64:1900-1905.
11. Aebi C., Cope L.D., Latimer J.L., Thomas S.E., Slaughter C.A., McCracken G.H., et al. Mapping of a protective epitope of the CopB outer membrane protein of Moraxella catarrhalis. Infect Immun 1998, 66:540-548.
12. Yang Y.P., Myers L.E., McGuinness U., Chong P., Kwok Y., Klein M.H., et al. The major outer membrane protein, CD, extracted from Moraxella (Branhamella) catarrhalis is a potential vaccine antigen that induces bactericidal antibodies. FEMS Immunol Med Microbiol 1997, 17:187-199.
13. Helminen M.E., Maciver I., Latimer J.L., Cope L.D., McCracken G.H., Hansen E.J. A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model. Infect Immun 1993, 61:2003-2010.
14. Murphy T.F., Kyd J.M., John A., Kirkham C., Cripps A.W. Enhancement of pulmonary clearance of Moraxella (Branhamella) catarrhalis following immunization with outer membrane protein CD in a mouse model. J Infect Dis 1998, 178:1667-1675.
15. Rahman M., Holme T., Jonsson I., Krook A. Lack of serotype-specific antibody response to lipopolysaccharide antigens of Moraxella catarrhalis during lower respiratory tract infection. Eur J Clin Microbiol Infect Dis 1995, 14:297-304.
16. Fomsgaard J.S., Fomsgaard A., Hoiby N., Bruun B., Galanos C. Comparative immunochemistry of lipopolysaccharides from Branhamella catarrhalis strains. Infect Immun 1991, 59:3346-3349.
17. Vaneechoutte M., Verschraegen G., Claeys G., Van Den Abeele A.M. Serological typing of Branhamella catarrhalis strains on the basis of lipopolysaccharide antigens. J Clin Microbiol 1990, 28:182-187.
18. Edebrink P., Jansson P.E., Rahman M.M., Widmalm G., Holme T., Rahman M., et al. Structural studies of the O-polysaccharide from the lipopolysaccharide of Moraxella (Branhamella) catarrhalis serotype A (strain ATCC 25238). Carbohydr Res 1994, 257:269-284.
19. Edebrink P., Jansson P.E., Rahman M.M., Widmalm G., Holme T., Rahman M. Structural studies of the O-antigen oligosaccharides from two strains of Moraxella catarrhalis serotype C. Carbohydr Res 1995, 266:237-261.
20. Hu W.G., Chen J., McMichael J.C., Gu X.X. Functional characteristics of a protective monoclonal antibody against serotype A and C lipooligosaccharides from Moraxella catarrhalis. Infect Immun 2001, 69:1358-1363.
21. Gu X.X., Chen J., Barenkamp S.J., Robbins J.B., Tsai C.M., Lim D.J., et al. Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis. Infect Immun 1998, 66:1891-1897.
22. Yu S., Gu X.X. Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis. Infect Immun 2005, 73:2790-2796.
23. Yu S., Gu X.X. Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis. Infect Immun 2007, 75:2974-2980.
24. Jiao X., Hirano T., Hou Y., Gu X.X. Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine. Infect Immun 2002, 70:5982-5989.
25. Edebrink P., Jansson P.E., Widmalm G., Holme T., Rahman M. The structures of oligosaccharides isolated from the lipopolysaccharide of Moraxella catarrhalis serotype B, strain CCUG 3292. Carbohydr Res 1996, 295:127-146.
26. Masoud H., Perry M.B., Richards J.C. Characterization of the lipopolysaccharide of Moraxella catarrhalis. Structural analysis of the lipid A from M. catarrhalis serotype A lipopolysaccharide. Eur J Biochem 1994, 220:209-216.
27. Wilson J.C., Collins P.M., Klipic Z., Grice I.D., Peak I.R. Identification of a novel glycosyltransferase involved in LOS biosynthesis of Moraxella catarrhalis. Carbohydr Res 2006, 341:2600-2606.
28. Zaleski A., Scheffler N.K., Densen P., Lee F.K., Campagnari A.A., Gibson B.W., et al. Lipooligosaccharide P(k) (Galalpha1-4Galbeta1-4Glc) epitope of Moraxella catarrhalis is a factor in resistance to bactericidal activity mediated by normal human serum. Infect Immun 2000, 68:5261-5268.
29. Peng D., Hu W.G., Choudhury B.P., Muszynski A., Carlson R.W., Gu X.X. Role of different moieties from the lipooligosaccharide molecule in biological activities of the Moraxella catarrhalis outer membrane. FEBS J 2007, 274:5350-5359.
30. Campagnari A.A., Spinola S.M., Lesse A.J., Kwaik Y.A., Mandrell R.E., Apicella M.A. Lipooligosaccharide epitopes shared among gram-negative non-enteric mucosal pathogens. Microb Pathog 1990, 8:353-362.
31. Mandrell R.E., Apicella M.A. Lipo-oligosaccharides (LOS) of mucosal pathogens: molecular mimicry and host-modification of LOS. Immunobiology 1993, 187:382-402.
32. Moran A.P., Prendergast M.M., Appelmelk B.J. Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease. FEMS Immunol Med Microbiol 1996, 16:105-115.
33. Peng D., Hong W., Choudhury B.P., Carlson R.W., Gu X.X. Moraxella catarrhalis bacterium without endotoxin, a potential vaccine candidate. Infect Immun 2005, 73:7569-7577.
34. Yu S., Xie H., Datta A., Naidu N., Gu X.X. Galactose residues on the lipooligosaccharide of Moraxella catarrhalis 26404 form the epitope recognized by the bactericidal antiserum from conjugate vaccination. Infect Immun 2008, 76:4251-4258.
35. York WS, Darvill AG, McNeil M, Stevenson TT, Albersheim P. Isolation and characterization of plant cell walls and cell wall components. Methods Enzymol 1985;118:3-40.
36. Ciucanu I., Kerek S F. A simple and rapid method for the permethylation of carbohydrates. Carbohydr Res 1984, 131:209-217.
37. Gupta R.K., Szu S.C., Finkelstein R.A., Robbins J.B. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect Immun 1992, 60:3201-3208.
38. Gu X.X., Tsai C.M. Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates. Infect Immun 1993, 61:1873-1880.
39. Dubois M., Gilles K., Hamilton J.K., Rebers P.A., Smith F. A colorimetric method for the determination of sugars. Nature 1951, 168:167.
40. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985, 150:76-85.
41. Gu X.X., Tsai C.M., Ueyama T., Barenkamp S.J., Robbins J.B., Lim D.J. Synthesis, characterization, and immunologic properties of detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins. Infect Immun 1996, 64:4047-4053.
42. Tsai C.M., Frasch C.E. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal Biochem 1982, 119:115-119.
43. Schwingel J.M., Edwards K.J., Cox A.D., Masoud H., Richards J.C., St Michael F., et al. The use of Moraxella catarrhalis lipooligosaccharide mutants to identify specific oligosaccharide epitopes recognized by human serum antibodies. Infect Immun 2009, 77:4548-4558.
44. Cox A.D., Zou W., Gidney M.A., Lacelle S., Plested J.S., Makepeace K., et al. Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits. Vaccine 2005, 23:5045-5054.